Related Experiment Videos
Cerebral venous sinus thrombosis risk across various oral contraceptives: a disproportionality analysis of the FDA
1Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA. alexandra_balshi@hms.harvard.edu.
Objective:
Estrogen-containing oral contraceptives (OCPs) increase the risk of thromboembolic events including cerebral venous sinus thromboses (CVSTs). However, robust pharmacovigilance data comparing CVST risk across OCPs remain limited.
Study Design:
The FDA Adverse Event Reporting System (FAERS) was used to investigate which OCPs are associated with a disproportionally high CVST reporting.
Results:
There were 479 reports of CVST across OCPs. Estrogen containing contraceptives were associated with disproportionally high CVST reporting, with ethinyl estradiol + drosperinone exhibiting the most substantial association (reporting odds ratio: 38.1, 345 cases).
Conclusion:
Clinicians should educate those taking estrogen-containing OCPs on how to identify CVST symptoms.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Birth Control Methods